The idea of using plant systems for the production of recombinant proteins has ceased to be a challenge to become a reality and alternative for the biopharmaceutical industry. There are several therapeutic products that are in various stages of preclinical and clinical development. However, within plant systems there is a wide variety, with the choice of plant expression system, crucial in the successful development of a biologic. Usually plant systems have a number of drawbacks at a molecular level, which decrease the level of expression of any exogenous protein therefore Agroaxis in collaboration with public is developing genetically modified plants to increase levels of expression. Currently, the development of these studies has led to tenfold increase production levels compared to other plant body, without affecting the product quality.